The cerebrospinal fluid immune microenvironment in lung cancer leptomeningeal metastasis: cellular ecosystems and therapeutic possibilities
- 1Department of Neurosurgery, Jilin Cancer Hospital , , ,
- 2Department of Neurosurgery, The Second Norman Bethune Hospital of Jilin University , , ,
Abstract
Leptomeningeal metastasis (LM) is a devastating form of central nervous system (CNS) dissemination in lung cancer, particularly non-small cell lung cancer (NSCLC). Current treatment frameworks emphasize CNS drug penetration, oncogenic driver evolution, and intrathecal therapy. Emerging evidence supports viewing the cerebrospinal fluid (CSF) compartment as an active tumor-immune space, but the field remains early, with limited lung cancer-specific mechanistic and single-cell datasets. Lung cancer cells in CSF appear to adapt to low protein content, limited nutrients, fluid shear, weak matrix support, and compartmental immune surveillance. Meanwhile, available CSF studies suggest immune states marked by exhausted T cells, regulatory lymphoid programs, suppressive myeloid remodeling, cytokine dysregulation, and tumor-supportive signaling. This review summarizes the CSF metastatic niche, tumor adaptation, immune-cell states, tumor-immune crosstalk, therapy-associated remodeling, and CSF multi-omics in lung cancer LM. We propose that CSF-guided profiling may help generate immune-state classifications and inform future targeted, intrathecal, immune, or combination strategies, while requiring prospective validation before routine treatment guidance.
Related
- From molecular mechanisms to clinical practice: advances in the immune microenvironment and translational therapeutics of colorectal cancer liver metastasis
- Tumor microenvironment-driven immune evasion in triple-negative breast cancer: mechanisms, clinical challenges, and therapeutic opportunities
- Comparative Therapeutic Validation of a Microfluidic Metastasis Model: Cimetidine but Not Cilengitide Inhibits Physiological Tumor Cell Extravasation.
- Antigen recognition licenses therapeutic CD8+ T cells to organize a multicellular myeloid interaction network in the tumor microenvironment
- Reprogramming the tumor microenvironment in mesothelioma: from immune suppression to therapeutic opportunity
BibTeX
@article{zhao2026cerebrospinal,
title = {{The cerebrospinal fluid immune microenvironment in lung cancer leptomeningeal metastasis: cellular ecosystems and therapeutic possibilities}},
author = {Yuanzheng Zhao and Haitao Guo and Yongchuan Guo},
journal = {Frontiers in immunology},
year = {2026},
month = sep,
doi = {10.3389/fimmu.2026.1959655},
url = {https://europepmc.org/article/PMC/PMC13662554},
note = {CC BY},
}
RIS
TY - JOUR
TI - The cerebrospinal fluid immune microenvironment in lung cancer leptomeningeal metastasis: cellular ecosystems and therapeutic possibilities
AU - Yuanzheng Zhao
AU - Haitao Guo
AU - Yongchuan Guo
PY - 2026
DA - 2026/09/30
JO - Frontiers in immunology
DO - 10.3389/fimmu.2026.1959655
UR - https://europepmc.org/article/PMC/PMC13662554
AB - Leptomeningeal metastasis (LM) is a devastating form of central nervous system (CNS) dissemination in lung cancer, particularly non-small cell lung cancer (NSCLC). Current treatment frameworks emphasize CNS drug penetration, oncogenic driver evolution, and intrathecal therapy. Emerging evidence supports viewing the cerebrospinal fluid (CSF) compartment as an active tumor-immune space, but the field remains early, with limited lung cancer-specific mechanistic and single-cell datasets. Lung cancer cells in CSF appear to adapt to low protein content, limited nutrients, fluid shear, weak matrix support, and compartmental immune surveillance. Meanwhile, available CSF studies suggest immune states marked by exhausted T cells, regulatory lymphoid programs, suppressive myeloid remodeling, cytokine dysregulation, and tumor-supportive signaling. This review summarizes the CSF metastatic niche, tumor adaptation, immune-cell states, tumor-immune crosstalk, therapy-associated remodeling, and CSF multi-omics in lung cancer LM. We propose that CSF-guided profiling may help generate immune-state classifications and inform future targeted, intrathecal, immune, or combination strategies, while requiring prospective validation before routine treatment guidance.
SN - 1664-3224
ER -